Molecules in the signaling pathway activated by gangliosides can be targets of therapeutics for malignant melanomas

Proteomics

Volumn 8, Issue 16, 2008, Pages 3312-3316

  Furukawa, Koichi ^a,c   Hamamura, Kazunori ^a   Nakashima, Hideyuki ^a   Furukawa, Keiko ^a,b  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CHUBU UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Glycosphingolipid; Integrin; Lipid raft; Signal; Tumor associated antigen

Indexed keywords

GANGLIOSIDE; GANGLIOSIDE ANTIBODY; GANGLIOSIDE GD2; GANGLIOSIDE GD3; GANGLIOSIDE GM2; TUMOR ANTIGEN;

CELL PROLIFERATION; HUMAN; LIPID RAFT; MELANOMA; MELANOMA CELL; MOLECULE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

GANGLIOSIDES; GLYCOSPHINGOLIPIDS; HUMANS; MELANOMA; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION;

EID: 50449086453     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.200800228     Document Type: Review

References (43)

1. Lloyd, K. O., Old, L. J., Human monoclonal antibodies to glycolipids and other carbohydrate antigens: Dissection of the humoral immune response in cancer patients. Cancer Res. 1989, 49, 3445-3451.
2. Furukawa, K., Lloyd, K. O., in: Ferrone, S. (Ed.), Gangliosides in Melanoma. Human Melanoma: From Basic Research to Clinical Application 1990 Springer, Heidelberg, pp. 15-30.
3. Portoukalian, J., Zwingelstein, G., Dore, J. F., Lipid composition of human malignant melanoma tumors at various levels of malignant growth. Eur. J. Biochem. 1979, 94, 19-23.
4. Carubia, J. M., Yu, R. K., Macala, L. J., Kirkwood, J. M., Varga, J. M., Gangliosides of normal and neoplastic human melanocytes. Biochem. Biophys. Res. Commun. 1984, 120, 500-5004.
5. Dippold, W. G., Lloyd, K. O., Li, L. T., Ikeda, H. et al., Cell surface antigens of human malignant melanoma: Definition of six antigenic systems with mouse monoclonal antibodies. Proc. Natl. Acad. Sci. USA 1980, 77, 6114-6118.
6. Houghton, A. N., Mintzer, D., Cordon-Cardo, C., Welt, S. et al., Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: A phase I trial in patients with malignant melanoma. Proc. Natl. Acad. Sci. USA 1985, 82, 1242-1246.
7. Yu, R. K., Macala, L. J., Taki, T., Weinfield, H. M. et al., Developmental changes in ganglioside composition and synthesis in embryonic rat brain. J. Neurochem. 1988, 50, 1825-1829.
8. Welte, K., Miller, G., Chapman, P. B., Yuasa, H. et al., Stimulation of T lymphocyte proliferation by monoclonal antibodies against GD3 ganglioside. J. Immunol. 1987, 139, 1763-1771.
9. Yamashiro, S., Okada, M., Haraguchi, M., Furukawa, K. et al., Expression of alpha 2,8-sialyltransferase (GD3 synthase) gene in human cancer cell lines: High level expression in melanomas and up-regulation in activated T lymphocytes. Glycoconj. J. 1995, 12, 894-900.
10. Nakaishi, H., Sanai, Y., Shibuya, M., Nagai, Y., Analysis of cellular expression of gangliosides by gene transfection. II: Rat 3Y1 cells transformed with several DNAs containing oncogenes (fes, fps, ras and src) invariably express sialosylparagloboside. Biochem. Biophys. Res. Commun. 1988, 150, 766-774.
11. Dippold, W. G, Knuth, A., Meyer zum Büschenfelde, K. H., Inhibition of human melanoma cell growth in vitro by monoclonal anti-GD3-ganglioside antibody. Cancer Res. 1984, 44, 806-810.
12. Miyazaki, H., Shiku, H., Furukawa, K., Differential effects of a murine monoclonal antibody reactive with the disialylgalactosyl residue on the growth of melanoma cells and T cell activation. Comparison with anti-GD3 antibody R24. Int. J. Oncol. 1996, 9, 241-245.
13. Irie, R. F., Matsuki, T., Morton, D. L., Human monoclonal antibody to ganglioside GM2 for melanoma treatment. Lancet 1989, 1, 786-787.
14. Nakano, J., Raj, B. K., Asagami, C., Lloyd, K. O., Human melanoma cell lines deficient in GD3 ganglioside expression exhibit altered growth and tumorigenic characteristics. J. Invest. Dermatol. 1996, 107, 543-548.
15. Nakano, J., Yasui, H., Lloyd, K. O., Muto, M., Biologic roles of gangliosides G(M3) and G(D3) in the attachment of human melanoma cells to extracellular matrix proteins. J. Investig. Dermatol. Symp. Proc. 1999, 4, 173-176.
16. Hamamura, K., Tsuji, M., Ohkawa, Y., Nakashima, H. et al., Focal adhesion kinase as well as p130Cas and paxillin is crucially involved in the enhanced malignant properties under expression of ganglioside GD3 in melanoma cells. Biochim. Biophys. Acta 2008, 1780, 513-519.
17. Hamamura, K., Furukawa, K., Hayashi, T., Hattori, T. et al., Ganglioside GD3 promotes cell growth and invasion through p130Cas and paxillin in malignant melanoma cells. Proc. Natl. Acad. Sci. USA 2005, 102, 11041-11046.
18. Kamimura, Y., Furukawa, K., Kittaka, D., Nishio, M. et al., Differential enhancing effects of alpha2,8-sialyltransferase on the cell proliferation and mobility. Int. J. Oncol. 2005, 26, 337-344.
19. Daniotti, J. L., Zurita, A. R., Trindade, V. M., Maccioni, H. J., GD3 expression in CHO-K1 cells increases growth rate, induces morphological changes, and affects cell-substrate interactions. Neurochem. Res. 2002, 27, 1421-1429.
20. Nojima, Y., Mimura, T., Morino, N., Hamasaki, K. et al., Tyrosine phosphorylation of p130Cas in cell adhesion and transformation. Hum. Cell 1996, 9, 169-174.
21. Defilippi, P., Di Stefano, P., Cabodi, S., p130Cas: A versatile scaffold in signaling networks. Trends Cell Biol. 2006, 16, 257-263.
22. Turner, C. E., Paxillin and focal adhesion signalling. Nat. Cell Biol. 2000, 2, E231-E236.
23. Schlaepfer, D. D., Mitra, S. K., Ilic, D., Control of motile and invasive cell phenotypes by focal adhesion kinase, Biochim. Biophys. Acta 2004, 1692, 77-102.
24. Cheresh, D. A., Harper, J. R., Schulz, G., Reisfeld, R. A., Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells. Proc. Natl. Acad. Sci. USA 1984, 81, 5767-5771.
25. Cheresh, D. A., Pytela, R., Pierschbacher, M. D., Klier, F. G. et al., An Arg-Gly-Asp-directed receptor on the surface of human melanoma cells exists in an divalent cation-dependent functional complex with the disialoganglioside GD2. J. Cell. Biol. 1987, 105, 1163-1173.
26. Aixinjueluo, W., Furukawa, K., Zhang, Q., Hamamura, K. et al., Mechanisms for the apoptosis of small cell lung cancer cells induced by anti-GD2 monoclonal antibodies: Roles of anoikis. J. Biol. Chem. 2005, 280, 29828-29836.
27. Stallcup, W. B., Pytela, R., Ruoslahti, E., A neuroectoderm-associated ganglioside participates in fibronectin receptor-mediated adhesion of germinal cells to fibronectin. Dev. Biol. 1989, 132, 212-229.
28. Burns, G. F., Lucas, C. M., Krissansen, G. W., Werkmeister, J. A. et al., Synergism between membrane gangliosides and Arg-Gly-Asp-directed glycoprotein receptors in attachment to matrix proteins by melanoma cells. J. Cell. Biol. 1988, 107, 1225-1230.
29. Zheng, M., Fang, H., Tsuruoka, T., Tsuji, T. et al., Regulatory role of GM3 ganglioside in alpha 5 beta 1 integrin receptor for fibronectin-mediated adhesion of FUA169 cells. J. Biol. Chem. 1933, 268, 2217-2222.
30. Simons, K., Ikonen, E., Functional rafts in cell membranes. Nature 1997, 387, 569-572.
31. Nakashima, H., Hamamura, K., Houjou, T., Taguchi, R. et al., Overexpression of caveolin-1 in a human melanoma cell line results in dispersion of ganglioside GD3 from lipid rafts and alteration of leading edges, leading to attenuation of malignant properties. Cancer Sci. 2007, 98, 512-520.
32. Samuel, B. U., Mohandas, N., Harrison, T., McManus, H. et al., The role of cholesterol and glycosylphosphatidylinositol-anchored proteins of erythrocyte rafts in regulating raft protein content and malarial infection. J. Biol. Chem. 2001, 276, 29319-29329.
33. Pollock, P. M., Meltzer, P. S., A genome-based strategy uncovers frequent BRAF mutations in melanoma. Cancer Cell 2002, 2, 5-7.
34. Madhunapantula, S. V, Robertson, G. P., Is B-Raf a good therapeutic target for melanoma and other malignancies? Cancer Res. 2008, 68, 5-8.
35. Nakamura, K., Hanibuchi, M., Yano, S., Tanaka, Y. et al., Apoptosis induction of human lung cancer cell line in multicellular heterospheroids with humanized antiganglioside GM2 monoclonal antibody. Cancer Res. 1999, 59, 5323-5330.
36. Livingston, P. O., Hood, C., Krug, L. M., Warren, N. et al., Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy. Cancer Immunol. Immunother. 2005, 54, 1018-1025.
37. Takahashi, T., Johnson, T. D., Nishinaka, Y., Morton, D. L. et al., IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients. J. Invest. Dermatol. 1999, 112, 205-209.
38. Zeng, G., Li, D. D., Gao, L., Birklé, S. et al., Alteration of ganglioside composition by stable transfection with antisense vectors against GD3-synthase gene expression. Biochemistry 1999, 38, 8762-8769.
39. Ko, K., Furukawa, K., Takahashi, T., Urano, T. et al., Fundamental study of small interfering RNAs for ganglioside GD3 synthase gene as a therapeutic target of lung cancers. Oncogene 2006, 25, 6924-6935.
40. Aoki, H., Satoh, M., Mitsuzuka, K., Ito, A. et al., FEBS Lett. 2004, 567, 203-208.
41. van Nimwegen, M. J., van de Water, B., Focal adhesion kinase: A potential target in cancer therapy, Biochem. Pharmacol. 2007, 73, 597-609.
42. McLean, G. W., Carragher, N. O., Avizienyte, E., Evans, J. et al., The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat. Rev. Cancer 2005, 5, 505-515.
43. Hehlgans, S., Haase, M., Cordes, N., Signalling via integrins: Implications for cell survival and anticancer strategies. Biochim. Biophys. Acta 2007, 1775, 163-180.